Forte Biosciences Files 8-K for Material Agreement
Ticker: FBRX · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1419041
Sentiment: neutral
Topics: material-agreement, corporate-event
TL;DR
Forte Biosciences signed a big deal on June 11th, details to come.
AI Summary
On June 11, 2024, Forte Biosciences, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company, formerly known as Tocagen Inc., is incorporated in Delaware and has its principal executive offices in Dallas, Texas. This filing also includes other events and financial statements/exhibits.
Why It Matters
This filing indicates a significant development for Forte Biosciences, potentially impacting its business operations and future strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement introduces uncertainty.
Key Numbers
- 001-38052 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-1243872 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- Tocagen Inc. (company) — Former company name
- June 11, 2024 (date) — Date of earliest event reported
- 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247 (location) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Forte Biosciences?
The filing states that Forte Biosciences, Inc. entered into a Material Definitive Agreement on June 11, 2024, but the specific terms and nature of this agreement are not detailed in this particular 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 11, 2024.
What was Forte Biosciences, Inc. formerly known as?
Forte Biosciences, Inc. was formerly known as Tocagen Inc.
Where are Forte Biosciences, Inc.'s principal executive offices located?
Forte Biosciences, Inc.'s principal executive offices are located at 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247.
What is the SIC code for Forte Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Forte Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,442 words · 6 min read · ~5 pages · Grade level 13 · Accepted 2024-06-14 16:05:53
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
- $25 million — raised gross proceeds of approximately $25 million (the "Private Placement"). Camac allege
Filing Documents
- d826178d8k.htm (8-K) — 36KB
- d826178dex101.htm (EX-10.1) — 58KB
- d826178dex991.htm (EX-99.1) — 65KB
- d826178dex992.htm (EX-99.2) — 77KB
- 0001193125-24-161592.txt ( ) — 414KB
- fbrx-20240611.xsd (EX-101.SCH) — 3KB
- fbrx-20240611_lab.xml (EX-101.LAB) — 18KB
- fbrx-20240611_pre.xml (EX-101.PRE) — 11KB
- d826178d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Standstill and Voting Agreement dated June 11, 2024, by and between the Company and the Camac Group. 99.1 Notice of Pendency of Derivative and Class Action, Proposed Settlement, and Settlement Hearing. 99.2 Stipulation and Agreement of Settlement, Compromise, and Release. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: June 14, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer